Extracorporeal Membrane Oxygenation Machine Market By Component (Pumps, Cannula), By Services (Veno-Venous, Veno-Arterial), By Patient Type (Adult, Pediatric), By Application (Respiratory, ECPR), And Region for 2026-2032

Extracorporeal Membrane Oxygenation Machine Market Valuation - 2026-2032

The growing advancements and the utilization of sophisticated sensor and monitoring systems enabling the real-time assessment and tracking of patient parameters is driving the growth of the Extracorporeal Membrane Oxygenation Machine Market. The growth of the healthcare industry, particularly in developing regions, is creating new opportunities for the ECMO market, surpassing USD 623.23 Million valued in 2024 to reach a valuation of around USD 932.81 Million by 2032.

In addition to this, the advancements in technology are enhancing the practice of healthcare professionals in the use of ECMO machines, thereby contributing to an increased utilization of these machines across diverse clinical environments. This technology is consequently leading to an increase in patient survival rates, enabling the niche market grow at a CAGR of 5.75% from 2026 to 2032.

Extracorporeal Membrane Oxygenation Machine Market: Definition/ Overview

The extracorporeal membrane oxygenation machine (ECMO) involves the external circulation of blood through a heart-lung machine. The device effectively eliminates carbon dioxide while delivering oxygen-enriched blood back to the circulatory system. The right side of the heart directs blood flow to the heart-lung machine. The substance is subsequently reheated and returned to the body.

ECMO works by channeling the patient's blood through an external circuit where it is oxygenated and carbon dioxide is removed before being returned to the body. It is commonly used in cases of severe cardiac failure, respiratory failure (such as ARDS or pneumonia), or post-cardiac surgery complications. ECMO is increasingly being applied in neonatal and pediatric care, where it has significantly improved survival rates for infants with congenital defects or severe respiratory distress. Its ability to temporarily take over the function of failing organs offers physicians a critical window to stabilize patients and address underlying causes of failure.

How are the Rising Incidence of Cardiac and Respiratory Conditions Propelling the Market Expansion?

The increasing prevalence of cardiopulmonary disorders is a significant issue, highlighting the necessity for enhanced medical interventions, including ECMO machines. Cardiac diseases, such as heart failure, myocardial infarction, and cardiac arrest, are on the rise due to factors like aging populations, sedentary lifestyles, poor diets, and increasing prevalence of risk factors such as hypertension, obesity, and diabetes. As these conditions often lead to life-threatening situations where traditional treatments may not suffice, ECMO systems are becoming essential in providing life support by maintaining oxygenation and circulatory functions while underlying conditions are treated.

Acute respiratory distress syndrome (ARDS) is characterized by the accumulation of fluid in the small air sacs of the lungs, impeding the efficient transfer of oxygen into the bloodstream. There is potential for escalation to severe respiratory issues, necessitating external assistance for effective breathing support. Cardiogenic shock represents a severe medical condition characterized by the heart's abrupt inability to effectively pump sufficient blood to meet the body's demands, leading to potential organ failure if not addressed promptly.

The rising patient population is leading to an escalating demand for ECMO machines. ECMO machines serve as substitutes for the heart and lungs, facilitating a period of rest and recovery for these vital organs. This technology has become essential in the intensive care unit for managing patients who do not respond to alternative treatments. The increasing prevalence of cardiopulmonary disorders is a significant factor influencing the ECMO machine market.

How Will the Elevated Expenses Associated with ECMO Machines and Procedures Hinder the Market Expansion?

The extracorporeal membrane oxygenation machine serves as a critical life support mechanism for individuals experiencing heart or lung failure. The core issue is that the substantial costs associated with ECMO machines, often reaching hundreds of thousands, represent a significant barrier to their utilization despite their remarkable capabilities. The procedure also requires highly specialized medical teams, including trained perfusionists, intensive care unit (ICU) staff, and continuous patient monitoring, which adds to labor costs and limits the number of hospitals capable of offering ECMO treatment.

This results from the utilization of cutting-edge technology and innovative materials in its production process. The overall cost is further influenced by the maintenance and operational expenses associated with these machines. ECMO procedures necessitate specialized teams of healthcare professionals, comprising surgeons, nurses, and percussionists, which contribute to the total treatment expenses.

Category-Wise Acumens

What are the Features Bolstering the Demand of Oxygenators Segment?

The oxygenators segment represented the most dominating segment in 2023 and is projected to continue its dominance throughout the forecast period. The rise in chronic diseases, particularly Chronic Obstructive Pulmonary Disease (COPD), alongside the growing need for heart and lung transplantation procedures, can explain this trend. The World Health Organization (WHO) reported that COPD ranked as the third leading cause of death worldwide, accounting for roughly 3.23 million fatalities. The significant increase in mortality rates associated with respiratory and cardiovascular diseases is driving the expansion of the Extracorporeal Membrane Oxygenation Machine Market.

The oxygenators segment is expected to benefit from the overall advancements in ECMO technology and its expanding use in broader clinical settings, including emergency and pediatric care. As healthcare systems adopt ECMO for more patients with severe cardiac and respiratory conditions, demand for high-performance oxygenators will likely increase. Furthermore, ongoing research into biocompatibility and longevity of oxygenators is set to improve patient outcomes and reduce the risks associated with long-term ECMO use, solidifying the market dominance of this segment.

How will the Demand for Veno-Arterial Segment Impacts the Market Growth?

The veno-arterial segment represented the fastest growing CAGR in 2023 and is projected to experience robust growth at a healthy CAGR throughout the forecast period. The increase in utilization can be linked to its effectiveness in managing cases of cardiac arrest, where it plays a crucial role in algorithm-driven life support techniques aimed at reestablishing blood circulation. The rising prevalence of chronic obstructive pulmonary disease (COPD) serves as a significant factor influencing this market segment. A research paper published by BMC Pulmonary Medicine in July 2022 indicated that around 300 million individuals are affected by COPD worldwide, with a prevalence rate of about 12.2%. This underscores a considerable demand for advanced life support technologies such as ECMO machines.

Innovations in VA-ECMO technology, such as more compact and efficient devices, and the integration of real-time monitoring systems, are likely to make it more accessible in emergency care and for long-term patient management. Moreover, expanding use in treating adult and pediatric patients with complex cardiac conditions, combined with advancements in postoperative recovery, will further drive the growth of this segment across hospitals and specialized care centers during the forecast period.

Country/Region-wise Acumens

How will the Growing Cardiac Issues Drives the Market in North America?

In 2023, the North America Extracorporeal Membrane Oxygenation Machine Market had the dominating share in terms of global revenues. North American market was predominantly represented by the U.S., which held the largest share in the global market. The nation possesses a robust healthcare infrastructure and a significant patient demographic in need of ECMO machines, attributed to the widespread occurrence of chronic illnesses and a notable rate of cardiac and respiratory failures. This has led to a higher demand for advanced life support systems like ECMO, particularly the veno-arterial (VA) type, which provides both cardiac and respiratory assistance in patients suffering from severe cardiac failure. With increasing numbers of patients requiring urgent intervention for heart-related complications, hospitals and medical centers are increasingly adopting ECMO technology as a critical tool for improving survival rates.

The U.S. has maintained its position as a global leader in the innovation of medical devices, drawing in leading manufacturers of ECMO machines. Major market players such as Medtronic, a prominent player in the medical technology sector, has achieved notable advancements in the ECMO machine market. The active participation of the U.S. in the development and approval processes for ECMO machines has led to a notable rise in adoption and expansion within this market segment.

How will the Increasing Adoption of Precision Medicine Supports the Market Growth in China?

Asia-Pacific region to grow at a robust CAGR during the forecast period. China is projected to maintain a leading role in the East Asia market for extracorporeal membrane oxygenation machines. The increasing utilization of ECMO in pediatric and neonatal care represents a significant factor influencing the industry in China. The evolving healthcare sector in the country is increasingly focused on improving clinical outcomes for infants and children suffering from life-threatening cardiorespiratory conditions.

In cases involving congenital heart defects, respiratory distress syndrome, and various severe infections in neonates, ECMO serves as a critical intervention when standard treatment options are inadequate. China is channeling investments into specialized pediatric and neonatal intensive care units across major hospitals, with ECMO machines emerging as essential equipment. The demand in China is driven by the government's dedication to enhancing health services for children, alongside the growing awareness among healthcare professionals regarding the effectiveness of ECMO in pediatric care.

Competitive Landscape

The Extracorporeal Membrane Oxygenation Machine Market is a dynamic and competitive landscape, with a mix of established players and emerging challengers vying for market share. These players are actively working to strengthen their presence by implementing strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are dedicated to continuously improving their product line to meet the needs of a wide range of customers in different regions.

Some of the key players operating in the Extracorporeal Membrane Oxygenation Machine Market include:

Medtronic, Fresenius Medical Care A.G. & Co. KGAA, Maquet Holding, Getinge Group, Microport, Origin Biomedical, Terumo Cardiovascular Systems Corporation, Livanova plc, Nipro Corporation, Euro sets S.R.L., Cytosorbents Corporation, Abiomed.

Latest Developments

In July 2023, the ASAIO Conference showcased BreathMo, an advanced ECMO system, highlighting China's innovation in the field of medical technology. This innovative maglev technology effectively meets the specific medical requirements of patients in China, representing a significant progression in the sector.

In April 2023, Abbott obtained two new approvals from the U.S. Food and Drug Administration (FDA) for its renowned life support system, specifically the CentriMag Blood Pump. The expanded FDA indication facilitates prolonged utilization in adults based on extracorporeal membrane oxygenation (ECMO), an essential life support technique for individuals experiencing cardiac and pulmonary complications.

In November 2022, LivaNova PLC announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation advanced circulatory support system, LifeSPARC. The approval indicates that the LifeSPARC system complies with the standards established by the FDA, allowing for its utilization in the U.S. market.

In July 2022, Inspira Technologies OXY B.H.N Ltd., a leader in life support technology, launched the "Liby" System. This sophisticated life support system is engineered to manage patients experiencing critical heart and lung failure.

In July 2021, Xenios AG, a subsidiary of Fresenius Medical Care, obtained approval from the National Medical Products Administration (NMPA) in China for the utilization of its Xenios Console and patient kits in ECMO therapy. The approval follows the successful registration of two patient kits in China.

Extracorporeal Membrane Oxygenation Machine Market, By Category

• Component:
• Pumps
• Oxygenator
• Controllers
• Cannula
• Accessories
• Services:
• Veno-Venous
• Veno-Arterial
• Arterio-Venous
• Patient Type:
• Neonates
• Pediatric
• Adult
• Application:
• Respiratory
• Neonates
• Pediatric
• Adult
• Cardiac
• Neonates
• Pediatric
• Adult
• ECPR
• Neonates
• Pediatric
• Adult
• Region:
• North America
• Asia-Pacific
• Europe
• South America
• Middle East & Africa